Search Results - "Friede, Martin"

Therapeutic antibodies for infectious diseases by Sparrow, Erin, Friede, Martin, Sheikh, Mohamud, Torvaldsen, Siranda

“…Passive immunization is the transfer of antibodies and occurs naturally during pregnancy. The transplacental transfer of maternal antibodies to the fetus can…”
Get full text

Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics by Vekemans, Johan, Moorthy, Vasee, Giersing, Brigitta, Friede, Martin, Hombach, Joachim, Arora, Narendra, Modjarrad, Kayvon, Smith, Peter G., Karron, Ruth, Graham, Barney, Kaslow, David C.

“…The respiratory syncytial virus causes a considerable respiratory disease burden globally, most markedly in young infants, in low and middle income countries…”
Get full text

A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future by Moore, Kristine A., Ostrowsky, Julia T., Kraigsley, Alison M., Mehr, Angela J., Bresee, Joseph S., Friede, Martin H., Gellin, Bruce G., Golding, Josephine P., Hart, Peter J., Moen, Ann, Weller, Charlotte L., Osterholm, Michael T., Ampofo, William, Barclay, Wendy, Cavaleri, Marco, Cohen, Cheryl, Cowling, Benjamin, Cox, Rebecca, Gust, Ian, Innis, Bruce, Kang, Gagandeep, Katz, Jacqueline, Krammer, Florian, Pitisuttithum, Punnee, Post, Diane, Rudenko, Larisa, Siqueira, Marilda, Weir, Jerry

“…Improved influenza vaccines are urgently needed to reduce the burden of seasonal influenza and to ensure a rapid and effective public-health response to future…”
Get full text

WHO/IVI global stakeholder consultation on group A Streptococcus vaccine development: Report from a meeting held on 12–13 December 2016 by Osowicki, Joshua, Vekemans, Johan, Kaslow, David C., Friede, Martin H., Kim, Jerome H., Steer, Andrew C.

“…While progress towards a Group A Streptococcus (GAS) vaccine has been stalled by a combination of scientific, regulatory, and commercial barriers, the problem…”
Get full text

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant by Coler, Rhea N, Bertholet, Sylvie, Moutaftsi, Magdalini, Guderian, Jeff A, Windish, Hillarie Plessner, Baldwin, Susan L, Laughlin, Elsa M, Duthie, Malcolm S, Fox, Christopher B, Carter, Darrick, Friede, Martin, Vedvick, Thomas S, Reed, Steven G

“…Innate immune responses to vaccine adjuvants based on lipopolysaccharide (LPS), a component of gram-negative bacterial cell walls, are driven by Toll-like…”
Get full text

A cost analysis of producing vaccines in developing countries by Munira, Syarifah Liza, Hendriks, Jan T., Atmosukarto, Ines I., Friede, Martin H., Carter, Louise M., Butler, James R.G., Clements, Archie C.A.

“…Developing country vaccine manufacturers (DCVMs) supply over half of the vaccines used in developing country immunisation programs. Decisions by developing…”
Get full text

Randomized Controlled Clinical Trial of Fractional Doses of Inactivated Poliovirus Vaccine Administered Intradermally by Needle-Free Device in Cuba by Resik, Sonia, Tejeda, Alina, Mas Lago, Pedro, Diaz, Manuel, Carmenates, Ania, Sarmiento, Luis, Alemañi, Nilda, Galindo, Belkis, Burton, Anthony, Friede, Martin, Landaverde, Mauricio, Sutter, Roland W.

“…Background. As part of an evaluation of strategies to make inactivated poliovirus vaccine (IPV) affordable for developing countries, we conducted a clinical…”
Get full text

Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial by Pitisuttithum, Punnee, Prof, Boonnak, Kobporn, PhD, Chamnanchanunt, Supat, MD, Puthavathana, Pilaipan, Prof, Luvira, Viravarn, MD, Lerdsamran, Hatairat, PhD, Kaewkungwal, Jaranit, PhD, Lawpoolsri, Saranath, MD, Thanachartwet, Vipa, MD, Silachamroon, Udomsak, MD, Masamae, Wanibtisam, MSc, Schuetz, Alexandra, PhD, Wirachwong, Ponthip, PhD, Thirapakpoomanunt, Sit, BPharm, Rudenko, Larisa, MD, Sparrow, Erin, MSc, Friede, Martin, PhD, Kieny, Marie-Paule, PhD

“…Summary Background The emergence of highly pathogenic avian influenza H5N1 viruses has raised concerns about their pandemic potential. Vaccination is the most…”
Get full text

A review of human vaccine research and development: Malaria by Girard, Marc P, Reed, Zarifah H, Friede, Martin, Kieny, Marie Paule

“…Abstract The last several years have seen significant progress in the development of vaccines against malaria. Most recently, proof-of-concept of…”
Get full text

Seasonal influenza vaccination policies in the 194 WHO Member States: The evolution of global influenza pandemic preparedness and the challenge of sustaining equitable vaccine access by Morales, Kathleen F, Brown, David W, Dumolard, Laure, Steulet, Claudia, Vilajeliu, Alba, Ropero Alvarez, Alba Maria, Moen, Ann, Friede, Martin, Lambach, Philipp

“…As of 2018, 118 of 194 WHO Member States reported the presence of an influenza vaccination policy. Although influenza vaccination policies do not guarantee…”
Get full text

Evolving pharmacovigilance requirements with novel vaccines and vaccine components by Zuber, Patrick L F, Gruber, Marion, Kaslow, David C, Chen, Robert T, Giersing, Brigitte K, Friede, Martin H

“…This paper explores the pipeline of new and upcoming vaccines as it relates to monitoring their safety. Compared with most currently available vaccines, that…”
Get full text

A Practical Guide to Full Value of Vaccine Assessments by Trotter, Caroline, Giersing, Birgitte, Lindstrand, Ann, Bar-Zeev, Naor, Cernuschi, Tania, Franzel-Sassanpour, Lauren, Friede, Martin, Hombach, Joachim, Jansen, Maarten, Hasso-Agopsowicz, Mateusz, Koh, Mitsuki, Sim, So Yoon, Spasenoska, Dijana, Yeung, Karene Hoi Ting, Lambach, Philipp

“…Articulating the wide range of health, social and economic benefits that vaccines offer may help to overcome obstacles in the vaccine development pipeline. A…”
Get full text

HIV immunoprophylaxis: preparing the pathway from proof of concept to policy decision and use by Vekemans, Johan, Snow, William, Fast, Patricia E, Baggaley, Rachel, Chinyenze, Kundai, Friede, Martin H, Godfrey-Faussett, Peter, Kaslow, David C, Rees, Helen

“…Various long-awaited efficacy studies of vaccines and broadly neutralising antibodies for prevention of HIV are now well underway in highly endemic settings…”
Get full text

Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation by Younis, Sumera Y, Barnier-Quer, Christophe, Heuking, Simon, Sommandas, Vinod, Brunner, Livia, Vd Werff, Nicole, Dubois, Patrice, Friede, Martin, Kocken, Clemens, Collin, Nicolas, Remarque, Ed

“…The need for rapid and accurate comparison of panels of adjuvanted vaccine formulations and subsequent rational down selection, presents several challenges for…”
Get full text

Decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines: an observational bias or a technical challenge? by Penttinen, Pasi M, Friede, Martin H

“…There are currently two types of approved influenza vaccines: inactivated or recombinant vaccines, and live attenuated vaccines. The live attenuated influenza…”
Get full text

Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants by Fox, Christopher B, Friede, Martin, Reed, Steven G, Ireton, Gregory C

“…Natural derivatives and synthetic analogues of lipopolysaccharide are potent stimulators of the mammalian immune system. Retained adjuvant activity with…”
Get more information

Bacillus Calmette-Guérin (BCG) vaccine: A global assessment of demand and supply balance by Cernuschi, Tania, Malvolti, Stefano, Nickels, Emily, Friede, Martin

“…Over the past decade, several countries across all regions, income groups and procurement methods have been unable to secure sufficient BCG vaccine supply…”
Get full text

Technology transfer programme for influenza vaccines – Lessons from the past to inform the future by Chadwick, Christopher, Friede, Martin, Moen, Ann, Nannei, Claudia, Sparrow, Erin

Get full text

Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: A World Health Organization Action Framework by Vekemans, Johan, Hasso-Agopsowicz, Mateusz, Kang, Gagandeep, Hausdorff, William P, Fiore, Anthony, Tayler, Elizabeth, Klemm, Elizabeth J, Laxminarayan, Ramanan, Srikantiah, Padmini, Friede, Martin, Lipsitch, Marc

“…This Action Framework identifies priority actions to prevent antimicrobial-resistant (AMR) through expanding the use of licensed vaccines, developing new…”
Get full text

Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications by Sparrow, Erin, Friede, Martin, Sheikh, Mohamud, Torvaldsen, Siranda, Newall, Anthony T

“…Abstract The Global Action Plan for influenza vaccines (GAP) aims to increase the production capacity of vaccines so that in the event of a pandemic there is…”
Get full text